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The immune mediators in echinoderms can be a potential source of novel antimicrobial peptides (AMPs) applied
toward controlling pathogenic staphylococcal biofilms that are intrinsically resistant to conventional antibiotics.
The peptide fraction <5 kDa from the cytosol of coelomocytes of the sea urchin Paracentrotus lividus (5-CC)
was tested against a group of Gram-positive and Gram-negative pathogen reference strains. The 5-CC of P. lividus
was active against all planktonic-tested strains but also showed antibiofilm properties against staphylococcal strains.
Additionally,wedemonstrated thepresenceof three smallpeptides in the5-CCbelonging to segment9-41ofaP. lividus
-thymosin. The smallest of these peptides in particular, showed the common chemical–physical characteristics of
AMPs. This novel AMP from -thymosin has high potential activity as an antibiofilm agent, acting on slow-growing
bacterial cells that exhibit a reduced susceptibility to conventional antibiotics and represent a reservoir for recurrent
biofilm-associated infections.
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Introduction
Staphylococci can induce a wide spectrum of infec-
tious diseases associated with remarkable morbid-
ity and mortality.1 Pathogenic staphylococci have
an extraordinary ability to acquire several antibi-
otic resistance traits, and the rise of community
and hospital-acquired methicillin-resistant Staphy-
lococcus aureus (MRSA) is a major health problem
worldwide. This scenario has created an urgent need
for novel therapeutic approaches2 to control drug-
resistant bacterial strains, not only in their free-
living planktonic form, but also when encountered
as biofilms—bacterial communities able to grow on
surfaces and surrounded by an extracellular poly-
meric substance (EPS) matrix.
The ability to form biofilms, is probably the most
important virulence factor of staphylococci in the
development of the chronic and persistent form of
several infectious diseases in humans such as otitis
media, osteomyelitis, endophtalmitis, urinary tract
infections, acute septic arthritis, native valve en-
docarditis, burn or wound infections, and cystic
fibrosis-associated pulmonary infections.3–9
Furthermore, staphylococcal biofilms are com-
monly isolated from medical device-related
infections with S. aureus mainly involved in metal-
biomaterial infections, while Staphylococcus epider-
midis is more often observed in polymer-associated
infections.10 The Gram-positive pathogens S. au-
reus, S. epidermidis, and Enterococcus faecalis repre-
sent more than 50% of the species isolated from
patients with medical device–associated infec-
tions,11 and catheter-related bloodstream infections
(CRBSIs) during intensive care unit (ICU) stays in
four European countries (France, Germany, Italy,
doi: 10.1111/j.1749-6632.2012.06652.x
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UK) have an estimated cost of € 163.9 million in
health care.12
Staphylococcal biofilm resistance to
antibiotics: a multifactorial mechanism
Bacterial biofilms aremore resistant tohost immune
defense systems and display a significantly high de-
gree of antibiotic tolerance.13 Antibiotic resistance
in biofilms is multifactorial, because biofilm struc-
tured bacteria develop different mechanisms of re-
sistance. The bacteria in the external layers of the
community, for example, are more active in cell di-
vision and energetic metabolism compared to the
internal layers, due to oxygen and nutrient gra-
dients from the top to the bottom of a biofilm.
A metabolically heterogeneous bacterial popula-
tion differsmarkedly froma free-living (planktonic)
population14 and nutrient-depleted zones can result
in stationary phase-like cells (dormant metabolic
state) with reduced susceptibility to antibiotics.15
The EPS matrix may retard the rate of penetra-
tion of antibiotics enough to induce the expression
of genes that mediate resistance within the biofilm.3
Other well-knownmechanisms such as the produc-
tion of enzymes that degrade antibiotics, alteration
of targets, or overexpression of efflux pumps that
have a broad range of substrates, are associated with
the planktonic cells, but bacterial cells growing in
biofilm increase horizontal gene transmission so
they can easily spread antibiotic resistance traits.16
Furthermore, specialized populations of persister
cells in the S. aureus biofilms, remain in a dormant
state in the presence of an antibiotic, with no growth
and no death.17 This mechanism is believed to be
responsible for recurrent infections in hospital set-
tings because the persister cells give rise to a normal
bacterial colony after drug removal.
It has been observed that S. aureus in biofilms is
100–1000 times less susceptible to antibiotics than
equivalent populations of planktonic bacteria.18
Conventional antibiotics can be effective against
metabolically active bacterial cells but currently no
effective therapies for staphylococcal biofilms exist.
Early removal of the device or surgical intervention,
remain the most effective means to treat biofilm-
associated infections, to date.4 Therefore, there is
an urgent need for novel treatments, strategies, and
antistaphylococcal biofilm agents.
Discovery of novel antistaphylococcal
biofilm agents
In the biofilm preclinical research field, three dif-
ferent approaches are primarily followed: screening
of novel compounds (synthetic or natural) that in-
hibit staphylococcal biofilms through direct effects
on bacterial growth and viability; target-based strat-
egy for discovering agents that show antibiofilm
properties by targeting specific pathways essential
for staphylococcal biofilm formation; and enzymes
that target staphylococcal biofilm matrix.19,20 This
paper will focus on discovery of novel antimicrobial
peptides (AMPs) derived from the beta-thymosin
peptide of Paracentrotus lividus as new antistaphy-
lococcal biofilm agents.
Activity-based screening of antibiofilm
agents
We focused on the immune system of marine in-
vertebrates as a relatively underexplored source of
new antimicrobial agents. Echinoderms are inter-
tidal benthic organisms that are constantly exposed
to a persistent threat of infection by high concen-
trations of bacteria and viruses from the marine
environment. The survival of these organisms de-
pends on efficient antimicrobial mechanisms that
protect them against pathogens. We focused on the
coelomocytes, the immune mediators in echino-
derms. In particular, our study focused on the sea
urchin, Paracentrotus lividus, which is a common
species in the Mediterranean sea. The coelomocytes
of echinoderms are responsible of a wide repertoire
of cellular and humoral immunologic functions, in-
cluding cellular recognition, phagocytosis, cytotox-
icity, and the production of antimicrobial peptides
(AMPs).21,22 In addition toAMPs, a 60-kDaprotein,
which showed antibacterial activity, has been iso-
lated from lysates of coelomocytes from P. lividus.23
The survival and fitness of P. lividus in marine envi-
ronments suggest that its innate immune system is
potent andeffective, since this species is a long-living
organism. Moreover, it lives in an infralitoral envi-
ronment where it is exposed to pathogenic attacks
from invading microorganisms also of anthropic
origin, and it is not fouled, so it clearly has de-
veloped strategies to prevent bacterial colonization
on its surface. All these biological and ecological as-
pects render the sea urchin P. lividus a good source
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for AMPs with high potential as novel antimicrobial
molecules.
Antimicrobial peptides (AMPs) are characterized
by a small molecular size (<10 kDa, or ∼10–50
amino acids) and broad antibacterial activity. A
large variety of AMPs have been described in ma-
rine invertebrates and represent the major humoral
defense system against pathogens: defensin, myt-
icin, and mytilin in mussels; penaeidin in shrimp;
tachyplesin; and polyphemusin in horseshoe crab;
clavanin; and styelin in ascidians, and Ci-PAP-A22
in Ciona intestinalis.24–32
AMPs in P. lividus have not been previously eval-
uated.We studied the antimicrobial and antistaphy-
lococcal biofilm activity of a 5-kDa peptide fraction
from coelomocytes cytosol (5-CC) against reference
strains and isolates of human and animal origin.
Biological activity of a 5-kDa peptide
fraction from coelomocytes cytosol
The 5-CC of P. lividus was tested against a Gram-
positive (S. aureus and S. epidermidis, including
drug-resistant strains) group and a Gram-negative
(Pseudomonas aeruginosa, E. coli) group, and plank-
tonic reference yeast (C. albicans, C. tropicalis)
strains by using a microdilution method and de-
termining the minimum inhibitory concentration
(MIC). The 5-CC showed a broad antimicrobial
activity against all tested strains (Table 1). More-
over, 5-CC showed antibiofilm properties against
staphylococcal biofilms of reference strains S. epi-
dermidis DSM 3269 and S. aureus ATCC 29213.
The antimicrobial efficacy of 5-CC against biofilms
of the clinical strain S. epidermidis 1457 was also
tested using live/dead staining in combination with
confocal laser scanning microscopy. At a sub-MIC
concentration (31.7 mg/mL) of 5-CC the forma-
tion of young (six hours old) and mature (24-hours
old) staphylococcal biofilms was inhibited. We ob-
served an interesting inhibitory effect of 5-CC at a
sub-MIC concentration, either on the formation of
a young biofilm (six hours old) of S. epidermidis
1457 or on the formation of a mature biofilm (24
hours old) of the same clinical strain (Fig. 1).36
The susceptibility to antimicrobial treatment of a
biofilm can depend on the stage of development
(age) of the biofilm itself. A mature biofilm can
be more tolerant to antimicrobial treatment than a
young biofilm. Live/dead staining was used to as-
say bacterial viability with or without treatment. As
Table 1. Antimicrobial activity of a 5 kDa peptide frac-
tion from celomocytes (5-CC)a
5-CC
MIC values in mg/mL
S. aureus 126.8
ATCC 29213
S. aureus 63.4
ATCC 25923
S. aureus 63.4
ATCC 43866
S. epidermidis 126.8
1457
S. epidermidis 253.7
DSM 3269
E. coli 126.8
ATCC 25922
P. aeruginosa 253.7
ATCC 9027
C. albicans 31.7
ATCC 10231
C. tropicalis 15.8
ATCC 13813
aValues in vitro expressed in mg/mL for all strains tested.
there was no sign of dead cells, the reduction in
bacterial adhesion could be due to an interference
of 5-CC peptides with microbial surface proteins
(adhesins, autolysins) that facilitate attachment to
surfaces in the first step of staphylococcal biofilm
formation.33,34
Considering that biofilms can be found in virtu-
ally all natural ecosystems that support microbial
growth, they also have enormous impact in veteri-
nary medicine because they can be responsible for
the failure in antimicrobial therapy in bacterial in-
fections or in a failure of properly sanitizing of food
processing plants. Many aspects of the farm man-
agement, in animal health and welfare and in food
processing premises should be reconsidered in the
light of these very common bacterial communities.
S. aureus is a major pathogen of mastitis, which is
one of the most common diseases in dairy cattle,
and we are currently testing the 5-CC against some
S. aureus isolates of animal origin. From prelimi-
nary experiments, we determined good antistaphy-
lococcal activity against planktonic S. aureus isolates
(MIC values ranging from 0.62 to 0.31 g/mL). We
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Figure 1. Preventative inhibitory activity of 5-CC. (Panel A) Staphylococcus epidermidis 1457 growth control (six hours old);
(panel B) treated with a concentration of 31.7 mg/mL after six hours; (panel C) S. epidermidis 1457 growth control (24 hours old);
(panel D) treated with a concentration of 31.7 mg/mL after 24 hours. After 6- or 24-h treatment, the biofilms were stained with
live/dead materials (SYTO9, green; PI, red) and observed using CLMS. The assays were repeated at least twice, and similar results
were obtained.36
also plan to evaluate the activity of 5-CCagainst pre-
formed 24-h-old biofilms of staphylococcal isolates
of veterinary importance.
AMPs from -thymosin of P. lividus
The antimicrobial defense system of marine inver-
tebrates is based solely on an innate immune system
that includes both humoral and cellular responses.
AMPs constitute a major component of their hu-
moral immunity. They are short cationic, amphi-
pathic sequences of amino acids ranging around
10–50 amino acids in length. Marine invertebrate
AMPs display broad antimicrobial spectra, even
against human pathogens.35
In our experimental work, we observed that
5-CC possessed a broad antimicrobial activity
against all tested pathogens. Small-sized molecules
with a broad antimicrobial spectrum are two
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common characteristics of AMPs, hence we em-
ployedRP-HPLC / nESI-MSMS to confirm the pres-
ence of AMPs in the 5-CC content. Three principal
peptides in 5-CC, whosemolecular weights were re-
spectively 1251.7, 2088.1, and 2292.2 Da, were iden-
tified: the (9–19), (12–31), and (24–41) fragments
of a -thymosin of P. lividus (NCBInr acc.no/gi/
22474470) whose molecular mass is 4592 Da.36
We found by BLAST analysis that -thymosin of
P. lividus has an identity of 87% with human
-thymosin 10.
The -thymosins are a family of highly con-
served polar 5-kDa peptides originally thought
to be thymic hormones. They are present at high
concentrations in almost every cell from vertebrate
phyla and have several biological functions due to
direct and indirect effects on the actin cytoskeleton.
There is little information about the function of
thymosins in invertebrates, but their presence has
been reported in marine invertebrates37,38 and in
insects where they are upregulated by microbial
infections.39
By analyzing some important chemical–physical
properties, such as hydrophobicity, charge, and
presence of hydrophobic residues on the same not
polar face, we found that the smallest fragment,
fragment 1, (9–19 of -thymosin), 11 amino acids
in length, has a good chance of being an antimi-
crobial peptide:40 it has a net positive charge be-
cause of an excess number of lysine residues, and
it has three hydrophobic residues on the same face
and a total hydrophobic ratio of 36%. Hydrophobic
and charged residues may permit interaction with
bacterial membranes.41 Moreover fragment 1 of
-thymosin has an alpha-helix structure, the most
common structure of AMPs in nature, and has a
similarity with already described AMPs produced
by a variety of organisms, for instance, a similarity
of 35% with the Jelleine III found in royal jelly of
honeybees (Apis mellifera).42
Fragment 2 (12–31 of -thymosin), 20 amino
acids in length, has a positive charge and a simi-
larity of 40.9% with maculatin, a peptide obtained
from skin glands of the tree frog Litoria genimac-
ulate.43 Fragment 3 (24–41 of -thymosin), and
-thymosin itself, are negatively charged and have
little chance to be AMPs.
Interestingly, the entire sequence fromaminoacid
9 to amino acid 41, may form alpha helices and
have at least five residues on the same hydrophobic
face. This region may interact with membranes and
has also good chance to be an AMP; moreover it
has a similarity of 39% with latarcins, antimicrobial
and cytolytic peptides from the venom of the spider
Lachesana tarabaevi (Table 2).44
AMPs from -thymosin of P. lividus as
potential antibiofilm agents
The tolerance of biofilms to antibiotics is mainly
due to the slow growth and low metabolic activity
Table 2. Chemical–physical properties of P. lividus -thymosin fragments and similarity with already described
AMPs
Percentage Sequence and hydrophobic
Total net hydrophobic residues (underlined) on Similarity
Peptide MW charge residues the same face (> 35%)
Fragment 1
(9–19)
1251.7 +1 36% E V A S F D K S K L K Jelleine III
Fragment 2
(12–31)
2293.2 +2 20% S F D K S K L K K A E T Q E K N T
L P T
Maculatin
Fragment 3
(24–41)
2088.1 −1 16% Q E KN T L P T K ET I EQE K T A
Entire sequence
(9–41)
3745.1 0 24% E V A S F D K S K L K K A E T Q E
K N T L P T K E T I E Q E K
T A
Latarcin
-thymosin 4583.1 −1 26% MADKPDVSEVASFDKSKLKKAE
(1–41) TQEKNTLPTKETIEQEKTA
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of bacteria in such communities, so they are intrin-
sically resistant to antibiotics, such as -lactams,
which target dividing and metabolically active cells.
On the contrary, the prevalent mechanism of ac-
tion of AMPs is due to their ability to permeabi-
lize and/or to form pores within the cytoplasmic
membranes, so they have a high potential to act
also on slow-growing or even nongrowing bacte-
ria that exhibit a reduced susceptibility to many
antibiotics and represent a reservoir for recurrent
biofilm infections. The AMPs also have a high po-
tential for inhibiting biofilm formation, in fact, they
can act at several stages of biofilm formation and
with differentmechanisms of action: theymaymin-
imize initial adhesion of microbial cells to abiotic
surfaces by altering the adhesive features of plastic
surfaces, or bybinding tomicrobial surfaces via elec-
trostatic interactions, or may prevent biofilm mat-
uration by killing the early surface colonizers, or by
inhibiting quorum sensing (QS), that is, the com-
munication system used by many bacteria to build
a biofilm.45
Staphylococcal biofilms are responsible for many
biomaterial associated infections (BAI), including
persistent forms of some infectious diseases in hu-
mans. The continual increase in the use of medi-
cal devices is associated with a significant risk of
infectious complications, including blood stream
infections, septic thrombophlebitis, endocarditis,
metastatic infections, and sepsis.46,47 Biofilm as-
sociated infections of indwelling medical devices
are usually resolved after replacement of the device
but involve a prolonged hospital stay and increased
healthcare costs. Considering also that increasing
numbers of elderly patients require indwellingmed-
ical devices like artificial knees and hips, a new
generation of antiinfective agents effective in the
prevention or eradication of biofilms is needed.48
AMPs derived from -thymosin of P. lividus
for their chemical–physical characteristics and
predicted activity are attractive candidates for po-
tential therapeutic development inmedical and vet-
erinary field. Our current experimental work is
aimed to confirm the predicted activity of the frag-
ments of-thymosin and to improve their potential
as novel effective chemical countermeasures against
staphylococcal biofims.
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